Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients
NCT ID: NCT03596398
Last Updated: 2018-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2016-01-01
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fabry Disease in Cerebrovascular Disease
NCT02859363
Stroke in Young Fabry Patients (sifap1): Frequency of Fabry Disease in Young Stroke Patients
NCT00414583
Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation
NCT00413595
Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease Patients
NCT05056636
Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy
NCT03230149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To measure the level of α-Gal A activity, male subjects will initially provide a DBS sample and female subjects will start with a test by whole blood sample.
The prevalence of Fabry disease among patients with young stroke will be estimated by a confirmative diagnosis in gene testing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Young stroke
Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
GLA gene
Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLA gene
Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged under 56 years old, not included 56
* Patients with acute stroke
* Patients and/or their legal representatives are willing to provide written informed consent
Exclusion Criteria
20 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Chiayi Christian Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
105028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.